Surf Bio Analysis: $16M Raised
What is Surf Bio?
Biopharmaceutical delivery using SnapShot technology
Location
Palo Alto, United States
Employees
1-10
Founded
2021
Product Features & Capabilities
- Surf SnapShot technology for biologics delivery
- High-concentration monoclonal antibody formulations
- Subcutaneous injection systems
- Proprietary polymer excipients for drug stabilization
Use Cases
Administer monoclonal antibodies in seconds instead of hours; Enable at-home self-administration for patients; Increase dosing intervals with higher concentrations; Collaborate with pharmaceutical companies for product pipelines; Develop formulations for diabetes and oncology therapies
Other Considerations
Raised $16 million in Series Seed financing; Established partnerships with leading pharmaceutical companies; Demonstrated in-vitro and in-vivo safety and efficacy data; Team includes industry veterans from Bigfoot Biomedical and Mode AGC
See something that needs updating? Suggest edits to this profile.